The Combined Use of 5 or More Drugs Is a Factor Related to Lower Adherence to S-1 in S-1 and Oxaliplatin Treatment for Advanced Gastric Cancer-Reference-Cited by-同舟云学术

The Combined Use of 5 or More Drugs Is a Factor Related to Lower Adherence to S-1 in S-1 and Oxaliplatin Treatment for Advanced Gastric Cancer

Published:2021-08-01 Issue:8 Volume:44 Page:1075-1080
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Kawakami Kazuyoshi¹,Aoyama Takeshi¹,Yokokawa Takashi¹,Kobayashi Kazuo¹,Takahari Daisuke²,Chin Keisho²,Ide Tsugumi³,Machida Yoshiaki³,Yamaguchi Kensei²,Hama Toshihiro¹

Affiliation:

1. Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research

2. Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research

3. Section for Practical Education, Hoshi University School of Pharmacy and Pharmaceutical Sciences

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/44/8/44_b21-00184/_pdf

Reference27 articles.

1. 1) Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 136, E359–E386 (2015).

2. 2) Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol., 9, 215–221 (2008).

3. 3) Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med., 358, 36–46 (2008).

4. 4) Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxalipalatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann. Oncol., 26, 141–148 (2015).

5. 5) Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res., 56, 2602–2606 (1996).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 胃がん術後CAPOX療法におけるカペシタビンの残薬評価;YAKUGAKU ZASSHI;2023-12-01

2. Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma;PLOS ONE;2023-11-16

3. S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis;PLOS ONE;2023-08-11

4. Sharing Patient Safety Management Skills in Oncology Pharmaceutical Outpatient Service;YAKUGAKU ZASSHI;2023-03-01